• Replaced gamma irradiation for prevention of GvHD
  • Avoided bacterial detection
  • Realized cost savings by reintroducing buffy coat platelets
  • Improved flexibility to produce platelets on-demand resulting from the reintroduction of buffy coat pooling
  • Reduction of transfusion reactions
  • Proactive protection against emerging pathogens

Collection Platform:
Trima

Platelet Suspension Medium:
InterSol (Fenwal)

INTERCEPT Disposable Set:
Large Volume, INT2203B
Dual Storage, INT2503B

Separation Platform:
Manual - 5 BC

Platelet Suspension Medium:
PAS - InterSol (Fenwal)

INTERCEPT Disposable Set:
Large Volume, INT2203B

 

Customer Profile:
Service Régional Vaudois de Transfusion Sanguine (SRTS VD)

Date of INTERCEPT Implementation
2011: Apheresis and Buffy Coat Platelets

Annual Collections

• 31,000 whole blood collections

Annual INTERCEPT Production
• 3,000 units of platelet concentrates
  - 60% Apheresis
  - 40% Buffy Coat

www.mavietonsang.ch

Lausanne Workflow

Quality Control Data
SRTS VD maintains a rigorous QC program in order to ensure the final blood product characteristics are in compliance with national requirements.  The tables below include SRCS’s QC data for INTERCEPT treated apheresis and buffy coat platelets.

 

Table 1: SRTS VD QC Results for INTERCEPT Platelets - Apheresis
Parameter
INTERCEPT Platelets
(Average ± SD)
N
Volume (mL)
307 ± 4
30
Platelet count (x1011 plt/unit)
3.5 ± 0.1
30
pH (Day 5) 7.05 ± 0.27 30

Table 2: SRTS VD QC Results for INTERCEPT Platelets - Buffy Coat
Parameter
INTERCEPT Platelets
(Average ± SD)
N
Volume (mL)
328 ± 13
60
Platelet count (x1011 plt/unit)
3.4 ± 0.1
60
pH (Day 5) 6.92 ± 0.08 60

^ back to top




Lausanne Tissot quote 2